Imaging PD-L1 Expression in Cancers Using 68Ga-NK224 PET

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of 68Ga-NK224 positron emission tomography/computed tomography (PET/CT) in assessing PD-L1 expression in cancerous tumors. Participants with newly diagnosed or previously treated malignant tumors will undergo PET/CT scans, and the results will be compared to histopathological findings to determine the diagnostic accuracy. The study aims to quantify tumor uptake using maximum and mean standard uptake values (SUVmax and SUVmean).

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (i) adult patients (aged 18 years or order);
* (ii) patients with newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report);
* (iii) patients who had scheduled 68Ga-NK224 PET/CT scans;
* (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

* (i) patients with non-malignant lesions;
* (ii) patients with pregnancy;
* (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Where it's running

• The First Affiliated Hospital of Xiamen University
  Xiamen, Fujian, China Recruiting

Study contacts

• Study coordinator: Liang Zhao
• Email: wzhaoliang01@163.com
• Phone: 86 0592-213-7366

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-dose local radiotherapy plus pucotenlimab with standard chemotherapy for advanced pancreatic cancer

  This trial tests whether adding low-dose local radiation and the PD-1 blocker pucotenlimab to standard chemotherapy can help people with advanced, unresectable pancreatic cancer.

  Recruiting Phase 1/2 Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT07312422

• Testing a blood test to predict response to cancer immunotherapy

  This study is testing a blood test to see if it can predict how well people with advanced cancer will respond to a specific type of immunotherapy.

  Recruiting at 3 sites Oxford Biodynamics Inc. · Norwich, Connecticut and 2 other locations · NCT06635954

• Combining Envafolimab with Chemoradiotherapy for Advanced Nasopharyngeal Cancer

  This study is testing if combining a new drug called Envafolimab with standard chemotherapy and radiation can help people with advanced nasopharyngeal cancer live longer without their cancer getting worse.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT05397769

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.